Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dbv Technologies ADR
(NQ:
DBVT
)
3.525
+2.912 (+475.04%)
Streaming Delayed Price
Updated: 9:49 AM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dbv Technologies ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
August 02, 2023
Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract.
Via
Benzinga
Earnings Preview: DBV Technologies
March 01, 2023
Via
Benzinga
Cambium Networks, SolarEdge Technologies, trivago And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 02, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies
August 01, 2023
DBV Technologies (NASDAQ: DBVT) received Type C meeting written responses from the FDA on key study design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies in 1 –...
Via
Benzinga
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
July 31, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
July 25, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
July 19, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
July 10, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023
June 16, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Participate in Upcoming EAACI Congress 2023
June 08, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
June 06, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 17, 2023
Via
Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via
Benzinga
Why Shares of DBV Technologies Jumped Thursday
May 11, 2023
The New England Journal of Medicine reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
Via
The Motley Fool
Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch
May 11, 2023
DBV Technologies (NASDAQ: DBVT) (OTC:
Via
Benzinga
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
May 10, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
May 09, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies Reports First Quarter 2023 Financial Results
May 04, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years
April 20, 2023
DBV Technologies (NASDAQ: DBVT) received written responses from the FDA on the regulatory path for the investigational Viaskin Peanut 250 μg patch (DBV712) in toddlers ages 1 – 3 years old with a...
Via
Benzinga
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
April 19, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
April 12, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
7 Penny Stocks Sitting in the Sweet Spot
March 26, 2023
If you can handle the ever-present threat of extreme volatility, these analyst-supported penny stocks could be interesting.
Via
InvestorPlace
Ordinary and Extraordinary General Meeting of April 12, 2023
March 24, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies Update
March 13, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 08, 2023
Via
Benzinga
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
March 07, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
March 02, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
March 02, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
February 27, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
February 21, 2023
From
DBV Technologies S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.